Opioid Use Disorder Market Information 2021-2030: Opioid Use Disorder Market Growth size was valued at USD 2,700 million in 2021 and is projected to reach around USD 5,200 million in 2030 exhibiting a CAGR of 8.5% in the forecasted period. The class of medications known as opioids includes medications that ease stress, lessen pain, and relax muscles. For the treatment of moderate-to-severe pain, doctors prescribe drugs such as hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other pharmaceutical opioids. Opioid usage disorder (OUD), a recurrent, chronic brain ailment, is typified by compulsive, despite-the-side-effects opioid seeking and use. Because it involves functional alterations to brain circuits associated to motivation, stress, selfcontrol, and decision-making, and because those changes may persist for a significant period of time after drug use has stopped, it is recognized as a brain condition. The signs of opioid use disorder include an intense desire to take opioids, a rise in opioid tolerance, and withdrawal symptoms after stopping. Request for A Sample of This Research Report @ https://wemarketresearch.com/samplerequest/opioid-use-disorder-market/890 Market Growth: The increase in the frequency of chronic illnesses such cancer, cardiovascular disease, and orthopaedic diseases is expected to fuel the expansion of the opioid use disorder market globally. The incidence of surgical intervention rises in proportion to the number of chronic conditions. Following surgery, pain is managed with opioid medications. Even after pain subsides, this risk may lead to opiate medication addiction. Thus, the demand for medications for opioid use disorder is expected to increase due to the rising prevalence of chronic diseases, which would accelerate market expansion. The market is growing because hydrochloride patches are becoming more and more recognized as an efficient treatment option. The market for opioid use disorder is expected to rise as buprenorphine patches gain popularity as an efficient treatment for opioid use disorder. Buprenorphine patches are thought to be a cutting-edge approach to treating opioid use disorder. Compared to alternative treatment modalities like injections, transdermal patches have a lot of advantages, such as the most comfortable medication delivery system, superior pain relief, and drug self-administration. Market Challenges: Drug administration side effects to limit market expansion The potential negative effects of the medications used to treat opioid addiction are one of the factors predicted to limit the growth of the market for treatment for opioid use disorders. These medications' common side effects, which are anticipated to impede market expansion, include nausea, vomiting, cramping in the abdomen, diarrhoea, respiratory issues, pain in the bones or joints, aches in the muscles, and constipation. Furthermore, in a
small number of extremely rare instances of a negative reaction, the patient may also have psychological issues including depression. hence limiting the growth of the market. Ask for Customization: https://wemarketresearch.com/customization/opioid-usedisorder-market/890 Market Trends and Drivers Increased Funding and Government Initiatives Governments worldwide are investing heavily in tackling the opioid crisis. In the U.S., federal programs such as the Comprehensive Addiction and Recovery Act (CARA) and the SUPPORT Act have allocated billions for OUD treatment and prevention. Rising Adoption of MAT MAT adoption is rising as stigma diminishes and healthcare providers recognize its efficacy in improving patient outcomes. Long-acting injectables and implants are particularly promising for enhancing adherence. Technological Innovations Digital health platforms and wearable devices are revolutionizing OUD care, enabling remote monitoring and personalized interventions. AI-powered tools are also being leveraged to predict relapse and optimize treatment plans. Opportunities and the Road Ahead Integrated Care Models Integrating OUD treatment with primary care and mental health services can improve outcomes and reduce the stigma associated with standalone addiction clinics. Focus on Prevention Prevention programs targeting at-risk populations, such as youth education campaigns and prescription monitoring systems, are gaining momentum. Global Expansion While the U.S. dominates the OUD market, there is growing potential in Europe, Asia, and other regions where opioid misuse is rising. Tailoring solutions to local contexts will be critical for market growth. Public-Private Partnerships Collaborations between governments, NGOs, and private companies can accelerate innovation and expand access to life-saving treatments. Market Geographically Analysis: North America is anticipated to maintain its position as the top revenue-generating area for the duration of the prediction. It held this position in 2021. The United States and Canada's
opioid problem is one of the main reasons supporting North America's largest market share. Various policies are being presented by administrations to control the emergency. For instance, the U.S. government launched an awareness-raising effort to combat opioid use in January 2018. In addition, it is anticipated that new medicines will enter the U.S. market over the predicted time. One such product is Brae burn’s CAM-2038 extra buprenorphine subcutaneous preparation, which may be administered once a month by injection. In contrast, Asia-Pacific was the second-largest market contributor in 2021 and is expected to grow at the fastest rate over the projected period due to an increase in the number of chronic illnesses, an increase in the number of elderly people, and increased awareness of healthcare services' accessibility. Some Major Companies Involved in this market are: 1. Indivior PLC 2. AL kermes 3. AstraZeneca 4. Brae burn 5. Orexin AB 6. Titan Pharmaceuticals, Inc. 7. Pear Therapeutics 8. Reckitt Benckiser Pharmaceuticals Inc. 9. Mallinckrodt Pharmaceuticals 10. Bio Delivery Sciences International Inc. 11. Vitric Inc. (Mylan N.V.) 12. Hickman Pharmaceuticals PLC 13. Camaros 14. Other players Market Segmentations: By Type •
Buprenorphine • Bun avail • Subclade • Sub Oxone • Subsoil • Others
By Drug Type • •
Agonist Antagonist
By Age Group
• • •
19 to 39 40 to 59 Age 60 and Over
By Route of Administration • • •
Oral Intravenous Sublingual
By Distribution Channel • • •
Hospital pharmacy Retail Pharmacy Online Pharmacy
Conclusion The opioid epidemic is a multifaceted challenge that demands a comprehensive and coordinated response. The OUD market offers significant opportunities for innovation, investment, and impact, but stakeholders must address existing barriers and prioritize patient-centered care. By leveraging technology, expanding access, and fostering collaboration, we can make meaningful strides toward ending the opioid crisis and improving the lives of millions worldwide. Click Here for Purchase Report @ https://wemarketresearch.com/purchase/opioid-usedisorder-market/890?license=single About We Market Research: WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets. Contact Us: Mr. Robbin Joseph Corporate Sales, USA We Market Research USA: +1-724-618-3925 Websites: https://wemarketresearch.com/ Email:
[email protected]
